"Complement C3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
| Descriptor ID |
D003176
|
| MeSH Number(s) |
D12.776.124.050.140 D12.776.124.486.274.250
|
| Concept/Terms |
Complement C3- Complement C3
- C3, Complement
- Complement 3
- Complement Component 3
- Component 3, Complement
- C3 Complement
- Complement, C3
Complement C3 Precursor- Complement C3 Precursor
- C3 Precursor, Complement
- Precursor, Complement C3
- Pro-C3
- Pro C3
- Precursor-Complement 3
- Precursor Complement 3
- Pro-Complement 3
- Pro Complement 3
- C3 Precursor
- Precursor, C3
|
Below are MeSH descriptors whose meaning is more general than "Complement C3".
Below are MeSH descriptors whose meaning is more specific than "Complement C3".
This graph shows the total number of publications written about "Complement C3" by people in this website by year, and whether "Complement C3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement C3" by people in Profiles.
-
Development of clinical and laboratory biomarkers in an international cohort of 428 children with lupus nephritis. Pediatr Nephrol. 2024 Oct; 39(10):2959-2968.
-
The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
-
Aptamer-Based Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome. Arthritis Rheumatol. 2022 07; 74(7):1223-1234.
-
Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
-
Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium. Lupus. 2021 Aug; 30(9):1394-1404.
-
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
-
Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth. PLoS One. 2020; 15(8):e0236968.
-
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020 04 01; 130(4):1912-1930.
-
A Case Report of Recurrent Lupus Nephritis 15 Days After Renal Transplantation. Transplant Proc. 2020 Mar; 52(2):614-618.
-
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.